• Eur. J. Clin. Invest. · Apr 2022

    CHA2 DS2 -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation.

    • Thomas Jensen, Pernille Gro Thrane, Kevin Kris Warnakula Olesen, Morten Würtz, NielsenJens CosedisJChttps://orcid.org/0000-0001-9414-1653Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Lisette Okkels Jensen, Morten Madsen, Troels Thim, Dalby KristensenSteenShttps://orcid.org/0000-0002-0112-0181Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark., LipGregory Y HGYHhttps://orcid.org/0000-0002-7566-1626Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK., and Michael Maeng.
    • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
    • Eur. J. Clin. Invest. 2022 Apr 1; 52 (4): e13717.

    AimsIn 2010, the European Society of Cardiology Guidelines on atrial fibrillation (AF) introduced the CHA2 DS2 -VASc score to guide initiation of oral anticoagulation. In patients with AF undergoing percutaneous coronary intervention (PCI), triple therapy with oral anticoagulation and dual antiplatelet therapy was recommended to reduce ischaemic risk. We examined how the CHA2 DS2 -VASc score impacted oral anticoagulation use and risks of ischaemic and hospitalized bleeding events in patients with AF undergoing PCI.MethodsWe included 6,014 patients with AF undergoing first-time PCI in Western Denmark between 2003 and 2017. We divided patients into four groups based on year of PCI and estimated 1-year risks of major adverse cardiac events (MACE) and hospitalization for bleeding.ResultsThe proportion of oral anticoagulation users was 48% in 2003-2006 and 49% in 2006-2010. Following the CHA2 DS2 -VASc score implementation, the proportion increased to 59% in 2011-2014 and 77% in 2015-2017. Using 2003-2006 as reference, risks of MACE were similar in 2007-2010 (adjusted relative risk [RRadj ] 0.99, 95% confidence interval [CI] 0.83-1.18) and 2011-2014 (RRadj 0.92, 95% CI 0.78-1.09), but declined by 23% in 2015-2017 (RRadj 0.77, 95% CI 0.65-0.92). Hospitalizations for bleeding did not increase despite wider use of triple therapy.ConclusionImplementation of the CHA2 DS2 -VASc score in the 2010 European guidelines on AF was associated with an increased utilization of oral anticoagulation and triple therapy among AF patients undergoing PCI. These changes were associated with a gradual decline in the risk of MACE, while the risk of hospitalized bleeding remained unchanged.© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…